BioLargo (BLGO) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2026, was $2.36 million, down 61% year-over-year due to the loss of a major private-label customer in 2025.

• Net loss for the six months was $7.41 million, compared to $3.80 million in the prior year period.

• The company operates in cleantech, focusing on odor/VOC control, water treatment, battery energy storage, and medical devices.

Financial highlights

• Product revenue fell 79% year-over-year for the quarter, while service revenue increased 7%.

• Gross profit for the six months was $1.13 million, down from $2.91 million year-over-year.

• Operating expenses rose to $8.06 million from $6.57 million, driven by higher R&D and SG&A.

• Net loss per share was $(0.02) for the six months, compared to $(0.008) in the prior year.

Outlook and guidance

• Management does not expect gross profits in 2026 to cover operational costs and anticipates the need for further investment capital.

• Substantial doubt exists about the company's ability to continue as a going concern without increased revenues or additional financing.